Private Prescription Weight Management: Wegovy vs Mounjaro Comparison
Why Choose Private Prescription for Wegovy 1.7mg Equivalent to Mounjaro Treatment
The private prescription route for Wegovy 1.7mg equivalent to Mounjaro eliminates the frustrating barriers of NHS weight management pathways. While NHS services require GP referral to specialist weight management clinics with 6+ month waiting lists and strict BMI criteria, private prescriptions through EverydayMeds provide immediate access to both semaglutide and tirzepatide treatments. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine Novo Nordisk Wegovy or Eli Lilly Mounjaro, identical to NHS-prescribed medications but without the procedural delays.
Private prescription patients comparing Wegovy 1.7mg equivalent to Mounjaro benefit from personalised clinical assessment within 3 working days, allowing treatment initiation while NHS patients remain on waiting lists. This timeline advantage is particularly valuable for individuals at the 1.7mg dose stage, representing weeks 13-16 of treatment where therapeutic momentum builds toward maintenance dosing. Our clinical team provides comparative guidance on both prescription-only medicines, ensuring your treatment choice aligns with lifestyle factors, storage requirements, and dosing preferences.
Wegovy 1.7mg vs Mounjaro Pricing and Value Through Private Prescription
Wegovy 1.7mg costs £139.99 per pen through EverydayMeds, positioning it competitively against Mounjaro pricing for equivalent treatment stages. Our Elevate Duo bundle (1.7mg + 2.4mg) at £369.99 provides seamless transition to maintenance dosing, while returning customers apply DOSE25 at checkout for optimal pricing. This transparent pricing structure eliminates NHS prescription charge uncertainty and provides clear cost forecasting for long-term weight management planning.
When comparing Wegovy 1.7mg equivalent to Mounjaro costs, consider the complete treatment journey rather than individual pen prices. Our Consistency 1.7mg bundle (×2 pens) at £309.99 supports extended dosing if maintenance transition requires additional time, while new customers benefit from FIRST40 discount code application. Private prescription costs remain predictable throughout treatment, contrasting with potential NHS prescription charge increases or treatment discontinuation due to funding restrictions.
Clinical Evidence: Wegovy 1.7mg Equivalent to Mounjaro Efficacy Comparison
Wegovy 1.7mg represents the penultimate dose before 2.4mg maintenance, corresponding to significant therapeutic effect development in the STEP trial programme. In STEP 1 trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks (Wilding et al., NEJM, 2021). The 1.7mg dose specifically marks weeks 13-16 where appetite suppression and satiety enhancement typically reach optimal levels before maintenance dosing.
Mounjaro (tirzepatide) operates through dual GIP and GLP-1 receptor agonism, while Wegovy targets GLP-1 receptors exclusively. Both prescription-only medicines demonstrated significant efficacy in their respective clinical programmes, though direct head-to-head comparisons remain limited due to different trial designs and populations. Your prescriber can evaluate which mechanism – semaglutide's established GLP-1 pathway or tirzepatide's dual hormone approach – suits your metabolic profile and treatment history.
How Wegovy 1.7mg Works Compared to Mounjaro Mechanisms
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones produced in your intestines after eating. This mechanism reduces appetite by acting on brain appetite centres in the hypothalamus, promoting earlier satiety signals and reducing food cravings between meals. The 1.7mg dose provides substantial GLP-1 receptor activation while maintaining tolerability before progressing to 2.4mg maintenance. Mounjaro's tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, creating dual hormone pathway activation. Both medications require administration alongside a reduced-calorie diet and increased physical activity for optimal therapeutic benefit.
Private Prescription Ordering Process for Wegovy 1.7mg Equivalent to Mounjaro
Begin your private prescription journey with our 3-minute online clinical assessment, covering medical history, current medications, and weight management goals relevant to both Wegovy and Mounjaro prescribing. Our registered prescribers review applications within 3 working days (24 hours with express service) and provide personalised recommendations on whether Wegovy 1.7mg or equivalent Mounjaro dosing suits your treatment stage. Following prescription approval, both medications ship via temperature-controlled cold-chain delivery within 24 hours to maintain pharmaceutical integrity. Payment processing includes automatic discount code application – FIRST40 for new customers or DOSE25 for returning patients – ensuring competitive pricing throughout your treatment journey. Our pharmacy team remains available for ongoing clinical support and prescription adjustments as you progress through dose escalation or consider switching between semaglutide and tirzepatide therapies.
Storage Advantages: Wegovy 1.7mg vs Mounjaro for Private Prescription Patients
Wegovy offers superior storage flexibility compared to Mounjaro, maintaining stability for 6 weeks at room temperature below 30°C once removed from refrigeration versus Mounjaro's 21-day limit. This storage advantage proves valuable for private prescription patients who travel frequently or lack consistent refrigeration access during the 1.7mg dosing phase. Both medications arrive in FlexTouch (Wegovy) or KwikPen (Mounjaro) pre-filled injection devices, requiring refrigeration at 2-8°C before first use. The dose escalation schedule for Wegovy progresses predictably through 0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg maintenance, while Mounjaro follows 2.5mg, 5mg, 7.5mg, 10mg, and optional 15mg progression. Private prescription patients benefit from flexible dose timing adjustments and clinical support throughout escalation phases with both prescription-only medicines.
Treatment Transition Planning: From Wegovy 1.7mg to Maintenance or Mounjaro Switching
The 1.7mg Wegovy dose represents a critical decision point for private prescription patients considering treatment optimisation or alternative therapy exploration. Patients achieving satisfactory progress at 1.7mg may continue to 2.4mg maintenance, while those experiencing tolerability concerns might explore Mounjaro's different mechanism profile. Our clinical team facilitates smooth transitions between semaglutide and tirzepatide therapies, managing washout periods and dose conversion calculations specific to your treatment history.
Private prescription flexibility allows personalised treatment pathways unavailable through NHS protocols, including extended 1.7mg dosing periods or accelerated progression to maintenance based on individual response. The Elevate Duo bundle specifically supports this transition phase, providing both current 1.7mg supply and subsequent 2.4mg maintenance dosing. Alternatively, patients may explore Mounjaro switching with appropriate clinical supervision, particularly if GLP-1 monotherapy provides insufficient therapeutic benefit compared to dual GIP/GLP-1 activation.
Start Your Private Prescription Journey: Wegovy 1.7mg or Mounjaro Selection
Both Wegovy and Mounjaro are available from EverydayMeds through private prescription, with personalised prescriber consultation to determine optimal treatment selection for your weight management goals. Access your Wegovy 1.7mg prescription at https://everydaymeds.co.uk/products/wegovy-1-7mg with transparent £139.99 pricing and immediate ordering capability. Apply DOSE25 at checkout for returning customer pricing, or FIRST40 for new patient discounts, ensuring competitive access to prescription-only weight management therapy. Our GPhC-registered pharmacy (#9012878) maintains pharmaceutical standards equivalent to NHS prescriptions while eliminating access barriers and waiting periods. Contact our clinical team today for expert guidance on whether Wegovy 1.7mg equivalent to Mounjaro suits your treatment timeline and therapeutic objectives.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
